Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Current Deferred Revenue (2023 - 2025)

Historic Current Deferred Revenue for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $111.9 million.

  • Monte Rosa Therapeutics' Current Deferred Revenue rose 34566.85% to $111.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.9 million, marking a year-over-year increase of 34566.85%. This contributed to the annual value of $117.2 million for FY2024, which is 26268.91% up from last year.
  • According to the latest figures from Q3 2025, Monte Rosa Therapeutics' Current Deferred Revenue is $111.9 million, which was up 34566.85% from $18.4 million recorded in Q2 2025.
  • Over the past 5 years, Monte Rosa Therapeutics' Current Deferred Revenue peaked at $117.2 million during Q4 2024, and registered a low of $18.4 million during Q2 2025.
  • For the 3-year period, Monte Rosa Therapeutics' Current Deferred Revenue averaged around $50.0 million, with its median value being $32.4 million (2023).
  • Data for Monte Rosa Therapeutics' Current Deferred Revenue shows a peak YoY increase of 34566.85% (in 2025) and a maximum YoY decrease of 4520.18% (in 2025) over the last 5 years.
  • Monte Rosa Therapeutics' Current Deferred Revenue (Quarter) stood at $32.3 million in 2023, then skyrocketed by 262.69% to $117.2 million in 2024, then fell by 4.55% to $111.9 million in 2025.
  • Its Current Deferred Revenue stands at $111.9 million for Q3 2025, versus $18.4 million for Q2 2025 and $32.6 million for Q1 2025.